# Allogenic UCMSCs as Adjuvant Therapy for Severe COVID-19 Patients

> **NCT05132972** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia** · enrollment: 42 (estimated)

## Conditions studied

- Covid 19

## Interventions

- **BIOLOGICAL:** Normoxic Allogenic UCMSC
- **OTHER:** Normal saline solution

## Key facts

- **NCT ID:** NCT05132972
- **Lead sponsor:** Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-17
- **Primary completion:** 2021-11
- **Final completion:** 2021-11
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2021-11-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05132972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05132972, "Allogenic UCMSCs as Adjuvant Therapy for Severe COVID-19 Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05132972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*